Creating a new treatment for ovarian cancer using targeted antibody-drug conjugates
Official title: Development of a Novel Nectin Targeting Antibody-drug Conjugate for Ovarian Cancer Therapy
Funded at Resonant Therapeutics, INC. · NIH-11008628 · Data updated 2026-11-12
This study is testing a new treatment that combines a special antibody with a powerful drug to specifically target and attack ovarian cancer cells, aiming to give patients more effective options when they have few choices left.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Resonant Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Santa Barbara, UNITED STATES) |
| Project start | September 19, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $371,070 |
| NIH project number | 1R43CA287873-01A1 |
| Project ID | NIH-11008628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with ovarian cancer, particularly those who have not responded well to existing therapies.
✕Less likely to help
Patients with non-ovarian cancers or those whose ovarian cancer does not express the targeted marker may not benefit from this research.
What this research studies
This research focuses on developing a novel antibody-drug conjugate (ADC) specifically designed to target ovarian cancer cells. By using a proprietary platform, the team has identified a new tumor-selective target that is overexpressed in ovarian cancer, which may also help to counteract the immunosuppressive environment of the tumor. The approach involves conjugating a cytotoxic drug to an antibody that binds to this target, allowing for precise delivery of the treatment directly to cancer cells. This method aims to improve therapeutic options for patients who currently have limited choices.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with ovarian cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise with similar antibody-drug conjugate approaches in treating various cancers, indicating potential for success with this novel target.
Where this research is happening
-
Resonant Therapeutics, INC.
Santa Barbara, United States Active
Researchers
- Principal investigator: Delgado, Oliver — Resonant Therapeutics, INC.
- Study coordinator: Delgado, Oliver
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.